- Home
- HTGC vs ARQT Comparison
HTGC vs ARQT Comparison
Compare HTGC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTGC | ARQT |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HTGC | ARQT |
|---|---|---|
| Price | $16.60 | $26.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $21.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | ★ 11.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $516,847,000.00 | $317,929,000.00 |
| Revenue This Year | $10.13 | $86.38 |
| Revenue Next Year | $9.62 | $30.29 |
| P/E Ratio | $9.58 | ★ N/A |
| Revenue Growth | 4.54 | ★ 129.21 |
| 52 Week Low | $15.65 | $11.13 |
| 52 Week High | $22.04 | $31.77 |
Technical Indicators
Market Signals| Indicator | HTGC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 46.88 |
| Support Level | $16.22 | $25.84 |
| Resistance Level | $17.00 | $27.62 |
| Average True Range (ATR) | 0.38 | 0.98 |
| MACD | -0.16 | 0.15 |
| Stochastic Oscillator | 15.12 | 62.18 |
Price Performance
Historical ComparisonAbout HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.